详情页 - 首都医科大学宣武医院知识库

当前位置：首页 > 详情页

Concurrent versus sequential whole brain radiotherapy and TKI in EGFR-mutated NSCLC patients with brain metastasis A single institution retrospective analysis

文献详情

资源类型：

收录情况： ◇ SCIE

作者：

机构： [a]Department of Oncology, the Second Affiliated Hospital of Soochow University, Jiangsu Province, Suzhou, [b]Cancer Center, Affiliated Hospital of Guangdong Medical University, Guangdong Province, Zhanjiang, [c]Department of Radiotherapy, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Province, Nanjing, [d]Department of Radiotherapy, Zhejiang Cancer Hospital, Zhejiang Province, Hangzhou, China

出处：

DOI：

ISSN：

关键词： brain metastasis concurrent EGFR mutation nonsmall cell lung cancer sequential tyrosine kinase inhibitors whole brain radiotherapy

摘要：

To examine the outcomes of concurrent versus sequential whole-brain radiotherapy (WBRT) and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in nonsmall cell lung cancer (NSCLC) patients with EGFR mutation. Retrospectively 105 patients with NSCLC, brain metastasis, and EGFR mutation (Affiliated Hospital of Guangdong Medical University, 01/2011 to 12/2014) were grouped as: EGFR-TKIs alone (n=39, group A), EGFR-TKIs+concurrent radiotherapy (n=34, group B), and radiotherapy followed by EGFR-TKIs (n=32, group C). The intracranial objective response rates of groups A, B, and C were 66.7%, 85.3%, and 75%, respectively (P<.05). The median intracranial progression-free survival of groups A, B, and C were 6.8, 12.4, and 9.1 months, respectively (P<.05). The median extracranial progression-free survival of groups A, B, and C were 7.8, 9.4, and 8.3 months, respectively (P>.05). EGFR-TKIs and WBRT by simultaneous application improved the short-and long-term benefits to patients with NSCLC brain metastasis carrying EGFR mutation compared to concurrent application or EGFR-TKIs alone without additional adverse events.

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2017]版：

大类 | 3 区医学

小类 | 3 区医学：内科

最新[2025]版：

大类 | 4 区医学

小类 | 4 区医学：内科

JCR分区：

出版当年[2016]版：

Q2 MEDICINE, GENERAL & INTERNAL

最新[2024]版：

Q2 MEDICINE, GENERAL & INTERNAL

影响因子： 1.4 最新[2024版] 1.6 最新五年平均 1.804 出版当年[2016版] 2.07 出版当年五年平均 2.133 出版前一年[2015版] 2.028 出版后一年[2017版]

第一作者：

第一作者机构： [a]Department of Oncology, the Second Affiliated Hospital of Soochow University, Jiangsu Province, Suzhou, [b]Cancer Center, Affiliated Hospital of Guangdong Medical University, Guangdong Province, Zhanjiang,

通讯作者：

通讯机构： [*1]Department of Oncology, the Second Affiliated Hospital of Soochow University, Jiangsu Province, Suzhou, China, Department of Radiotherapy, Zhejiang Cancer Hospital, Zhejiang Province, Hangzhou, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]The correlation between EGFR mutation status and the risk of brain metastasis in patients with lung adenocarcinoma [2]Management of brain metastases: History and the present [3]Clinical and radiological predictors of epidermal growth factor receptor mutation in nonsmall cell lung cancer [4]Efficacy and safety of PD-1 inhibitors plus anti-angiogenesis tyrosine kinase inhibitors with or without transarterial chemo(embolization) for unresectable hepatocellular carcinoma: a meta-analysis [5]Relationship between circulating lung-specific X protein messenger ribonucleic acid expression and micrometastasis and prognosis in patients with early-stage nonsmall cell lung cancer [6]Anaplastic lymphoma kinase tyrosine kinase inhibitors associated gastrointestinal obstruction, perforation, and ulceration: an analysis of the FDA adverse event reporting system database (FAERS) [7]Dosimetric comparison of the helical tomotherapy, volumetricmodulated arc therapy and fixed-field intensity-modulated radiotherapy for stage IIB-IIIB nonsmall cell lung cancer [8]Activation of G-Protein-Coupled Estrogen Receptor Inhibits the Migration of Human Nonsmall Cell Lung Cancer Cells via IKK-beta/NF-kappa B Signals [9]Local Thermal Ablation with Continuous EGFR Tyrosine Kinase Inhibitors for EGFR-Mutant Non-small Cell Lung Cancers that Developed Extra-Central Nervous System (CNS) Oligoprogressive Disease [10]EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases